Compare NUAI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NUAI | CBIO |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | 5 | 44 |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 633.1M | 557.8M |
| IPO Year | N/A | N/A |
| Metric | NUAI | CBIO |
|---|---|---|
| Price | $6.74 | $17.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $11.00 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 8.3M | 239.8K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $279.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $8.72 |
| 52 Week High | $9.45 | $27.41 |
| Indicator | NUAI | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 69.98 | 44.91 |
| Support Level | $3.71 | $17.02 |
| Resistance Level | $7.59 | $21.60 |
| Average True Range (ATR) | 0.72 | 1.41 |
| MACD | 0.15 | -0.06 |
| Stochastic Oscillator | 87.33 | 37.75 |
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.